Efficacy of selpercatinib as tyrosine kinase inhibitor in RETmutant medullary thyroid cancer: a systematic review

被引：0
|
作者：
Margouw, R. Relia [1 ]
Santoso, A. Febrian [1 ]
Maulidia, S. Azrianindita [1 ]
Kurniawan, A. [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO4-5
引用
收藏
页码：S1330 / S1330
页数：1
相关论文
共 50 条
  • [41] The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells
    Vitagliano, Donata
    De Falco, Valentina
    Tamburrino, Anna
    Coluzzi, Sabrina
    Troncone, Giancarlo
    Chiappetta, Gennaro
    Ciardiello, Fortunato
    Tortora, Giampaolo
    Fagin, James A.
    Ryan, Anderson J.
    Carlomagno, Francesca
    Santoro, Massimo
    ENDOCRINE-RELATED CANCER, 2011, 18 (01) : 1 - 11
  • [42] Tyrosine kinase inhibitors in thyroid cancer
    Illouz, Frederic
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2010, 14 (07): : 210 - 214
  • [43] A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo DISCUSSION
    Weber, Collin J.
    Cohen, Mark S.
    Chen, Herb
    SURGERY, 2010, 148 (06) : 1236 - 1236
  • [44] Efficacy and safety of selpercatinib in advanced RET-altered thyroid cancers: A meta-analysis and systematic review
    Muhibullah
    Shafique, Nouman
    Kaur, Navneet
    Ahmed, Jawad
    Zain, Sarmad
    Naqvi, Syed Mujtaba Ali
    Bajwa, Shammas
    Nawaz, Hassan
    Rehman, Atta Ur
    Haider, Ali
    Ghaffar, Ali
    Javeed, Zainab
    Iqbal, Abdul Ghani
    Ehsan, Amna
    Khanal, Prajjwal
    Shafique, Adeena
    Shafiq, Iqra
    Kumar, Besham
    Hussain, Rida
    Rizwan, Umer
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer
    Hadoux, J.
    Elisei, R.
    Brose, M. S.
    Hoff, A.
    Robinson, B.
    Gao, M.
    Jarzab, B.
    Isaev, P.
    Kopeckova, K.
    Wadsley, J.
    Fuhrer, D.
    Keam, B.
    Sherman, E. J.
    Tahara, M.
    Hu, M. I.
    Lin, Y.
    Maeda, P.
    Wirth, L. J.
    Castillon, J. Capdevila
    ANNALS OF ONCOLOGY, 2023, 34 : S1338 - S1338
  • [46] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Zohreh Maghsoomi
    Zahra Emami
    Ramin Malboosbaf
    Mojtaba Malek
    Mohammad E. Khamseh
    BMC Cancer, 21
  • [47] LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer
    Wirth, Lori J.
    Brose, Marcia S.
    Elisei, Rossella
    Capdevila, Jaume
    Hoff, Ana O.
    Hu, Mimi, I
    Tahara, Makoto
    Robinson, Bruce
    Gao, Ming
    Xia, Meng
    Maeda, Patricia
    Sherman, Eric
    FUTURE ONCOLOGY, 2022, 18 (28) : 3143 - 3150
  • [48] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
  • [49] Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, ret-mutant medullary thyroid cancer
    Hadoux, Julien
    Elisei, Rosella
    Brose, Marcia
    Hoff, Ana
    Robinson, Bruce
    Gao, Ming
    Jarzab, Barbara
    Isaev, Pavel
    Kopeckova, Katerina
    Wadsley, Jonathan
    Fuehrer, Dagmar
    Keam, Bhumsuk
    Sherman, Eric
    Tahara, Makoto
    Hu, Mimi
    Lin, Yan
    Maeda, Patricia
    Wirth, Lori
    Capdevila, Jaume
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 228 - 228
  • [50] Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer
    De Leo, Simone
    Trevisan, Matteo
    Sarto, Giulia Vanessa Re
    Moneta, Claudia
    Pirovano, Marta
    Colombo, Carla
    Cosmai, Laura
    Fugazzola, Laura
    THYROID, 2023, 33 (09) : 1130 - 1132
12345